Results 21 to 30 of about 28,304 (252)

Achievement and Features Associated with Childhood Definition of Remission in Juvenile-Onset Systemic Lupus Erythematosus. [PDF]

Turk Arch Pediatr
OBJECTIVE: To identify the feasibility of achieving the childhood definition of remission, investigate factors affecting achievement and determine the concordance rate with adult definition in children with systemic lupus erythematosus (SLE). MATERIALS AND METHODS: Medical records of children diagnosed with SLE between 2012 and 2022 were reviewed.
Kisaoglu H, Baba O, Kalyoncu M.
europepmc   +2 more sources

The role of assessment of renal biopsy in electron microscopy in making a diagnosis of juvenile-onset systemic lupus erythematosus in a 16-year-old female patient with depression and proteinuria – case report

Central European Journal of Immunology, 2022
The course of juvenile-onset systemic lupus erythematosus may vary, from rapid multiorgan involvement to insidious development mimicking different medical conditions.
Tomasz Koszutski, Agnieszka Wiernik, Lidia Hyla-Klekot, Natalia Matysiak, Grażyna Kucharska   +4 more
doaj   +1 more source

Abstract 13 — Comparison of Clinical and Serological Features in Juvenile and Adult-Onset Systemic Lupus Erythematosus

Journal of Clinical Rheumatology and Immunology, 2023
Background Systemic lupus erythematosus (SLE) has varying clinical and serological features in juvenile and adult-onset disease groups, depending on the ethnicity. Objectives: To compare the disease characteristics of patients with adult-onset (ASLE) and
Babur Salim, Anum Khan, Haris Gul, Saba Samreen, Shahida Perveen   +4 more
doaj   +1 more source

POS1308 SINGLE CENTER REAL-LIFE PRACTICE OF BIOLOGICAL THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH JUVENILE ONSET

Annals of the Rheumatic Diseases, 2022
In recent years the use of Biologics (B) at the management of systemic lupus erythematosus including with juvenile onset (jSLE) has increased. Belimumab (BEL) became the first approved B for SLE. The use of rituximab (RTM), despite the status “of label”,
M. Kaleda, I. Nikishina, E. Fedorov, S. Salugina, A. Shapovalenko, T. Pachkoria   +5 more
semanticscholar   +1 more source

Juvenile systemic lupus erythematosus presenting only as nonscarring alopecia

Indian Journal of Paediatric Dermatology, 2022
Juvenile onset systemic lupus erythematosus (JSLE) is a rare multisystem, autoimmune disorder. Alopecia in SLE generally follows a pre-established disease with systemic symptoms. A 13-year-old girl presented with sudden hair loss over the vertex of scalp
N M Vinitha, Reena Rai, G Uma Maheswari
doaj   +1 more source

Macrophage activation syndrome triggered by systemic lupus erythematosus flare: successful treatment with a combination of dexamethasone sodium phosphate, intravenous immunoglobulin, and cyclosporine: a case report

Journal of Medical Case Reports, 2021
Background Macrophage activation syndrome is classified as a secondary form of hemophagocytic lymphohistiocytosis. It is a hyperinflammatory complication observed to be comorbid with a variety of autoimmune diseases, including adult-onset Still’s disease
Wesam Gouda, Faisal Alsaqabi, Abdelhfeez Moshrif, Awad S. Abbas, Tarek M. Abdel-Aziz, Md Asiful Islam   +5 more
doaj   +1 more source

Association of Individual or Family History of Autoimmune Disease With Future Development of Type 1 Diabetes. [PDF]

Diabetes Metab Res Rev
ABSTRACT Timely diagnosis of type 1 diabetes (T1D), especially in high‐risk populations, is crucial for preventing serious health complications. T1D is a chronic progressive autoimmune disease that has presymptomatic stages that can be identified through the detection of islet autoantibodies. Given that T1D is associated with other autoimmune diseases,
Thomas N, Vaidya B, Leslie RD, Agardh D, Oram R, Dabelea D, Singh A, Chantzichristos D, Rewers M.   +8 more
europepmc   +2 more sources

FRI0123 Cumulative tissue damage in patients with juvenile-onset systemic lupus erythematosus [PDF]

Annals of the Rheumatic Diseases, 2001
Background In earlier studies, we found that the juvenile onset of systemic lupus erythematosus (SLE) did not significantly modify the clinical expression of the disease.1 Although juvenile-onset SLE may have a more sombre prognosis than adult-onset SLE, there have been few comparative studies of these types of SLE.
I Monteagudo, FJ López-Longo, CM González, AI Turrión, CA Montilla, M Moreno-Zazo, N Caro, R Del Castillo, C González-Montagut, L Cebrián, E Carmona, L Carreño   +11 more
openaire   +1 more source

Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile‐Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature

Arthritis & Rheumatology, 2023
Patients with juvenile‐onset systemic lupus erythematosus (JSLE) have increased atherosclerosis risk. This study investigated novel atherosclerosis progression biomarkers in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial ...
Junjie Peng, Pierre Dönnes, S. Ardoin, L. Schanberg, L. Lewandowski, G. Robinson, E. Jury, C. Ciurtin   +7 more
semanticscholar   +1 more source

Subclinical atherosclerosis in young Thai adults with juvenile-onset systemic lupus erythematosus [PDF]

Asian Biomedicine, 2016
Abstract Background Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in adult patients with systemic lupus erythematosus (SLE). Increased risk of CVD and atherosclerosis has been demonstrated in children with SLE.
Nalinee Pattrakornkul, Patamakom Pruangprasert, Prakul Chanthong, Ratana Chawanasuntorapoj, Anirut Pattaragarn   +4 more
openaire   +1 more source